Oxford, UK – 6 April, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that it has signed a new three year Development & Supply Agreement (“DSA”) with Boehringer Ingelheim for the manufacture and supply of various types of viral… Read More
Oxford, UK – 3 February, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces two changes to the Group’s Board of Directors. Professor Dame Kay Davies will be joining the Board as a Non-Executive Director, effective 1 March 2021. Professor… Read More
Oxford, UK – 18 January, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announces today that the Prime Minister Rt Hon Boris Johnson MP, has formally opened Oxford Biomedica’s new 84,000 sq ft manufacturing facility Oxbox based in Oxford, UK. Oxbox… Read More
Oxford, UK – 30 December, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes AstraZeneca PLC (“AstraZeneca”) has announced that their COVID-19 Vaccine, formerly AZD1222, has been authorised for emergency supply in the UK by The UK Medicines and Healthcare products… Read More
-Ends- Oxford, UK – 3 December, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that, John Dawson, Chief Executive Officer of Oxford Biomedica, was named Executive of the Year in the category for Companies with… Read More
Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes AstraZeneca PLC (“AstraZeneca”) announced AZD1222 met primary efficacy endpoint in preventing COVID-19. Key highlights from the announcement were as follows: Two different dosing regimens demonstrated efficacy with… Read More
Oxford, UK – 23 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that, with effect from 1 December 2020, Dr. Siyamak (“Sam”) Rasty has been appointed to the Group’s Board as a Non-Executive Director. Dr. Rasty… Read More
Collaboration to develop next-generation CAR-T cell therapies with improved efficacy and durability PhoreMost’s SITESEEKER platform will identify active peptides to be deployed within Oxford Biomedica’s LentiVector® delivery system Oxford, UK – 9 November, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group… Read More
Oxford, UK – 6 October, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes Axovant Gene Therapies’ (“Axovant”) positive six-month follow-up data from the second cohort of the SUNRISE-PD Phase 2 trial of AXO-Lenti-PD gene therapy in Parkinson’s disease. Key highlights… Read More
Oxford, UK – 6 October, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has issued a Certificate of GMP compliance for the fourth GMP manufacturing suite within the Group’s… Read More
Oxford, UK – 17 September 2020: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2020. FINANCIAL HIGHLIGHTS • Revenue increased by 6% to £34.0 million (H1 2019: £32.1 million) Continued… Read More
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public… Read More